Related Experiment Video
Updated: Jul 10, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
Published on: May 17, 2019
Prevention of cancer through immunization: Prospects and challenges for the 21st century
Ian H Frazer1, Doug R Lowy, John T Schiller
1Diamantina Institute for Cancer Immunology and Metabolic Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. i.frazer@uq.edu.au
Abstract:
Persistent infection by several microbial agents is responsible for at least 15% of cancer globally, including most cancers of the liver, stomach, and cervix. The recent development of vaccines that can prevent infection and premalignant disease caused by human papillomaviruses (HPV), which cause virtually all cases of cervical cancer as well as some other cancers, has focused renewed attention on infection control as a means of reducing the global cancer burden. For vaccines to prevent cancer-causing infection with hepatitis C virus, Helicobacter pylori, or Epstein Barr virus, new vaccine technologies to induce more effective protective responses are required. For the two available cancer control vaccines, designed to prevent infection with HPV and hepatitis B virus, the major challenge is to promote effective vaccine deployment through education programs and increased affordability/accessibility for underserved populations, particularly in the developing world, where the cancer burden attributable to infection by these two viruses is greatest.
Insights
Infection control, including vaccination, is key to reducing the global cancer burden. New vaccine technologies and improved access are needed to prevent infection-related cancers like cervical and liver cancer.
Area of Science:
- Oncology
- Infectious Diseases
- Vaccinology
Background:
- Microbial infections are linked to at least 15% of global cancers, including liver, stomach, and cervical cancers.
- Human papillomaviruses (HPV) cause nearly all cervical cancers, highlighting the potential of vaccines in cancer prevention.
- Existing vaccines target HPV and hepatitis B virus (HBV), but broader vaccine development is needed for other infection-related cancers.
Purpose of the Study:
- To review the role of infection control in reducing the global cancer burden.
- To discuss the challenges and opportunities in developing and deploying cancer-preventive vaccines.
- To emphasize the need for new vaccine technologies and improved accessibility, especially in developing nations.
Main Methods:
- Literature review of microbial agents linked to cancer.
- Analysis of current vaccine technologies for cancer prevention.
- Examination of deployment strategies for HPV and HBV vaccines.
Main Results:
- Persistent microbial infections contribute significantly to the global cancer incidence.
- Vaccines against HPV and HBV are available but require enhanced deployment strategies.
- Development of novel vaccines is necessary for preventing cancers caused by agents like hepatitis C virus, Helicobacter pylori, and Epstein-Barr virus.
Conclusions:
- Infection control through vaccination is a critical strategy for global cancer reduction.
- Addressing vaccine accessibility and affordability is paramount, particularly in underserved regions.
- Continued research into novel vaccine technologies is essential to combat a wider range of infection-related cancers.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Cancer Prevention
Some...
Cancer Prevention
Some...
Vaccinations
Microorganisms in Medicine and Therapeutics

